{"filings":[{"id":696717,"accession_number":"0001193125-26-242009","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-05-27T20:35:50+00:00","items":["4.01","9.01"],"status":"ready","headline":"Allurion Technologies dismisses Deloitte & Touche, appoints CBIZ; discloses material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche LLP dismissed as independent auditor effective May 22, 2026; Audit Committee approved.","No adverse opinions or disagreements on accounting principles in fiscal years 2024 and 2025.","Material weaknesses in internal controls existed for FY2024, FY2025, and interim period through May 22, 2026, related to segregation of duties, staffing, and IT controls.","CBIZ CPAs P.C. appointed as new independent auditor for FY2026, effective May 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111362,"accession_number":"0001193125-26-104434","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Allurion appeals NYSE delisting; trading moves to OTC; FDA approval of balloon catalyst for relisting plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.","Trading suspended after March 6, 2026; common stock and warrants now trade on OTCID Market under ALUR and ALUR.WS.","Company appealed delisting determination and will attempt to regain compliance with NYSE or list on NYSE American.","FDA approval of Allurion Gastric Balloon System (Feb 20, 2026) catalyzed plan to strengthen balance sheet and fund U.S. commercialization.","CEO Dr. Shantanu Gaur expressed confidence in executing the plan to treat obesity in over 100M Americans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111361,"accession_number":"0001193125-26-084412","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Allurion receives NYSE delisting notice for non-compliance with equity/market cap standard; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified Allurion it fails Section 802.01B: requires ≥$50M stockholders' equity or ≥$50M market cap on 30-day average.","Company intends to appeal; shares expected to continue trading on NYSE during the appeal process.","Recent FDA approval on Feb 20, 2026 cited as catalyst for regaining compliance or relisting on another exchange.","Also pursuing debt-for-preferred exchange with largest creditor and completed warrant inducement on Feb 24, 2026.","No guarantee of success; risk of delisting and negative impact on liquidity and capital access if appeal fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111360,"accession_number":"0001193125-26-068667","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Allurion warrant inducement: $3M gross proceeds, exercise price cut to $1.15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercising holders purchase 2,659,565 shares at $1.15; Company expects $3.0M gross proceeds.","Existing warrants from Jan 2025 ($6.00), Feb 2025 ($5.23), Nov 2025 ($1.67) amended to $1.15 exercise price.","Company issues new warrants for up to 5,319,130 shares at $1.15, exercisable after stockholder approval, 5-year term.","Roth Capital Partners serves as financial advisor; receives 5% fee on gross proceeds plus up to $40,000 expenses.","Company to file resale registration statement for new warrant shares within 60 calendar days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111359,"accession_number":"0001193125-26-062599","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA grants PMA approval for Allurion gastric balloon system for obesity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Allurion Smart Capsule approved for adults 22-65 with BMI 30-40 kg/m² after unsuccessful weight loss attempt.","Balloon swallowed in 15-min office visit, no surgery/endoscopy/anesthesia; stays ~4 months, then passes naturally.","AUDACITY pivotal trial data supported approval; over 200,000 patients treated outside US with 14% total body weight loss.","Opens access to ~80 million US adults with obesity; alternative to GLP-1s and bariatric surgery.","Company cited 65% GLP-1 discontinuation rate within first year and rapid weight regain as unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111358,"accession_number":"0001193125-26-010462","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q4 revenue up 22-37% QoQ; FY2025 revenue ~$15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $3.3-3.7M (22-37% QoQ increase); full-year revenue ~$15M.","Substantial QoQ and YoY improvement in operating expenses and operating loss.","CEO cites strategic pivot taking hold; potential FDA approval of Allurion Smart Capsule in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":15230000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127972,"accession_number":"0001193125-25-327032","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allurion stockholders approve reverse stock split, equity plan amendment, and other proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to serve until 2028 annual meeting.","Ratified Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2025.","Approved amendment to 2023 Stock Option and Incentive Plan, increasing share reserve and allowing repricing of outstanding options.","Approved issuance of common stock upon conversion of Series B Preferred and exercise of private placement warrants for NYSE compliance.","Approved reverse stock split amendment in range 1:1.5 to 1:20; Board to set exact ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127971,"accession_number":"0001193125-25-276066","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Allurion becomes debt-free via preferred equity exchange, raises $5M, Q3 revenue falls 50%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged all Notes and RIFA debt for Series B convertible preferred stock with $1,000 stated value, 8.25% dividend; company becomes debt-free.","Raised $5M via private placement at $1.67 per share plus warrant exercisable at $1.67 for five years.","Q3 revenue $2.7M (down 50% YoY); gross margin 49%; operating loss $9.6M (improved 22% YoY); adjusted operating loss $6.9M.","Cash $6.1M at Sep 30 (excluding private placement); operating expenses cut 29% YoY.","FDA cleared pre-approval and BIMO audits with zero observations; entered substantive PMA review; completed Day-100 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127970,"accession_number":"0001193125-25-230301","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allurion director Milena Alberti-Perez resigns; board reduces to eight members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Milena Alberti-Perez resigned from the Board and Audit Committee chair, effective Sept 30, 2025.","Resignation not due to any disagreement; she is focusing on media sector and a new public board role.","Board size reduced from nine to eight; Audit Committee chair replacement under evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144752,"accession_number":"0001193125-25-180926","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Allurion restates financials for 2023-2024 and Q1 2025 due to fair-value accounting errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on prior financial statements for annual periods 2023-2024 and Q1 2025 due to RIFA and Notes fair value errors.","Errors are non-cash; affect OCI, other income/expense, net income; no impact on revenue, gross margin, or cash.","Company to restate via amendments to annual report and Q1 2025 10-Q; material weaknesses previously disclosed.","Audit committee concluded restatement necessary; no recoupment under compensation recovery policy expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144751,"accession_number":"0000950170-25-107634","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.","Operating loss improved to $7.0M from $9.3M YoY; cash $12.7M as of June 30.","Restructuring charges ~$1.5M in Q3 2025; FY2025 guidance being re-evaluated.","Potential restatement of non-cash OCI/other income related to RIFA and convertible notes; no impact on revenue, gross margin, opex, or cash.","New strategy: focus on low-dose GLP-1 combo therapy, muscle mass maintenance; FDA PMA accepted for Allurion Balloon; term sheet signed for drug-eluting balloon."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":8959000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144750,"accession_number":"0000950170-25-104347","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","2.05","7.01","9.01"],"status":"ready","headline":"Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.","Restructuring: workforce reduction of ~70 employees (~65% of total); estimated severance charges of ~$1.5M; completion expected by end of Q3 2025.","Signed term sheet with strategic partner for ex-US distribution and potential joint development of a GLP-1 drug-eluting intragastric balloon.","Submitted protocol to IRBs for prospective study on low-dose GLP-1 + Allurion Program for weight loss and muscle preservation; enrollment expected in 2025.","PMA application for Allurion Balloon accepted by FDA for evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":8959000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163149,"accession_number":"0000950170-25-070934","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q1 revenue $5.6M, net operating loss narrows 36% YoY; maintains FY 2025 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue of $5.6M (down 40% YoY); gross margin expanded to 75% from 73% YoY.","Operating expenses fell 37% YoY to $11.4M; adjusted OpEx of $10.1M, down 45%.","Net operating loss of $7.3M, down 36% YoY; adjusted loss $5.9M, down 48%.","Cash balance $20.4M; FY 2025 revenue guidance reaffirmed at ~$30M with ~50% OpEx reduction.","Completed Pre-PMA meeting with FDA; final PMA module submission expected by end of June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":5580000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163148,"accession_number":"0000950170-25-055398","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Allurion amends notes; $5M converted at $3.35 as market cap falls below $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Note Purchase Agreement with RTW Investments added conversion provisions triggered by sub-$15M market cap.","On April 16, 2025, mandatory conversion of $5M principal into 1,492,537 shares at floor price $3.35/share.","Purchasers may convert up to $5M additional at agreed rate (capped at $3.35) and up to $5M at 5-day VWAP less 5%.","Monthly conversion option allows up to $1M/month ($12M max) at 5-day VWAP rate until April 15, 2026.","Purchasers agreed to vote shares issued under new provisions in proportion to other holders or abstain, subject to 9.9% threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163147,"accession_number":"0000950170-25-052927","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allurion stockholders approve warrant repricing and conversion price reductions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved repricing of July 2024 warrants: 2,601,734 for, 292,618 against.","Approved issuance upon exercise of Jan 2025 warrants: 2,787,134 for, 264,121 against.","Approved issuance upon exercise of Feb 2025 warrants: 2,601,694 for, 263,870 against.","Approved reduction of conversion price on up to $10M notes if market cap falls below $15M: 2,589,686 for.","Approved additional conversion price reduction on up to $17M notes for one year: 2,584,817 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163146,"accession_number":"0001193125-25-072475","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allurion postpones special meeting to April 10, 2025 for further proxy solicitation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting postponed from April 4 to April 10, 2025 at 12:00 p.m. ET via virtual webcast.","Record date of March 14, 2025 remains unchanged; prior proxies remain valid unless revoked.","Board unanimously recommends voting FOR all proposals as described in the proxy statement.","Postponement aims to allow more time for stockholder participation and proxy solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181068,"accession_number":"0000950170-25-044805","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.","Q4 operating loss $17.1M vs $25.7M YoY, includes $4.6M restructuring and financing costs.","Q4 gross margin 45% vs 78% YoY; full-year 67%; expects margin expansion in 2025.","Sales resumed in France Feb 12, 2025; positive AUDACITY FDA trial readout; next-gen balloon launched.","Cash $15.4M at Dec 31, 2024; recent financings expected to fund through potential FDA approval in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181067,"accession_number":"0001193125-25-031990","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Allurion raises ~$6.1M via registered direct offering and private placement to fund GLP-1 clinical pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).","Also issued 267,686 shares and 535,372 warrants to Leavitt Equity Partners at $5.23/share in a concurrent private placement.","Total gross proceeds expected to be ~$6.1M; net proceeds will fund muscle mass/GLP-1 adherence trials, working capital, and general corporate purposes.","As consideration, company will seek stockholder approval to reduce exercise price of Leavitt’s July 2024 warrants from $30.00 to $6.00 per share.","Offering closed on February 20, 2025; Roth Capital Partners acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181066,"accession_number":"0001193125-25-026187","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allurion relaunches balloon in France after ANSM clearance; exploring combo GLP-1 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ANSM cleared Allurion to resume sales of Allurion Balloon in France, effective immediately (Feb 13, 2025).","France historically represented approximately 15% of Allurion's revenue.","Company plans clinical trial combining balloon with GLP-1s to study prevention of muscle loss during GLP-1 therapy.","Previous study: patients with balloon gained 5.6% lean body mass while losing 14% total weight over 4 months.","Another study: 167 patients lost 15.7% weight with no change in muscle mass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181065,"accession_number":"0001193125-25-013703","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Allurion raises ~$7.5M through registered direct offering and private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $7.5 million from sale of 1,240,000 shares at $6.00 per share with accompanying warrants.","Warrants to buy 1,240,000 additional shares at $6.00, exercisable upon stockholder approval, expire in five years.","Company to seek shareholder approval to reprice July 2024 warrants for participating investors from $30 to $6 per share.","Net proceeds to be used for working capital and general corporate purposes.","Offering closed on January 27, 2025; Roth Capital Partners served as exclusive placement agent with 7% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181064,"accession_number":"0001193125-25-007863","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["1.01","2.02","9.01","3.02"],"status":"ready","headline":"Allurion raises $2.5M via private placement; prelim Q4 rev $5.6M, FY rev ~$32M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 841,751 shares at $2.97/share for gross proceeds of $2.5M; option for additional $10M.","Preliminary Q4 2024 revenue ~$5.6M; full-year revenue ~$32M, in line with guidance.","Procedure volume growth (ex-France) ~4%, ahead of previously issued guidance.","Proceeds extend runway through early 2026; used for working capital and general corporate purposes.","Investment from funds affiliated with RTW Investments, LP; Roth Capital Partners acted as sole financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181063,"accession_number":"0001193125-25-003236","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Allurion amends notes/RIFAs with cash & revenue covenants, FDA/France deadlines; reports AUDACITY trial topline results","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.","Deadlines: French marketing authorization by Dec 31, 2025; FDA US marketing authorization by June 30, 2026.","Amendment fee: 5% fully-diluted shares to investors after $12M+ offering by Feb 15, 2025; else Series A-1 preferred redeemable Dec 31, 2026.","RTW gets second board seat; Jason Richey appointed to board alongside Nicholas Lewin.","Announced topline results from AUDACITY trial of Allurion Balloon; details in press release Exhibit 99.4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181062,"accession_number":"0001193125-25-002254","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allurion appoints R. Jason Richey to Board as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 8 to 9; Richey appointed effective December 30, 2024.","Richey is an independent consultant to RTW Investments, a company stockholder.","Previously president/CEO of Cytrellis Biosystems and president of Cutera (CUTR).","Compensation consistent with Allurion's non-employee director compensation policy.","No other arrangement or material interest in transactions with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197948,"accession_number":"0001193125-24-287091","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Allurion to effect 1-for-25 reverse stock split on Jan 3, 2025 to cure NYSE bid price deficiency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding shares reduced from ~67.78M to ~2.71M; effective 12:01 a.m. ET Jan 3, 2025.","CUSIP number changes to 02008G 201; trading symbol ALUR remains unchanged.","Each public warrant (ALUR WS) becomes exercisable for 0.056818 shares at $202.50 per share.","Company received NYSE deficiency letter on Aug 12, 2024 due to bid price below $1.00 for 30 days.","No fractional shares issued; fractional holders automatically rounded up to next whole share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197947,"accession_number":"0000950170-24-137992","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allurion shareholders approve reverse stock split and share issuances at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors re-elected: Shantanu Gaur, Krishna Gupta, Nicholas Lewin; votes for ranged 27.2M-33.7M.","Reverse stock split approved (1:10 to 1:25 ratio); 39.9M for, 1.3M against; Board to set exact ratio.","Issuance of shares upon conversion of Notes under Note Purchase Agreement approved (33.6M for, 2.0M against).","Issuance of shares upon conversion of Series A Preferred and exercise of Private Placement Warrants approved (33.5M for).","Ratification of Deloitte & Touche as independent auditor for FY2024 (40.7M for, 0.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197946,"accession_number":"0000950170-24-125961","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allurion CFO Christopher Geberth resigns; CEO Shantanu Gaur assumes financial officer role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Christopher Geberth resigned effective Nov 13, 2024 to pursue other interests; no disagreement cited.","CEO Shantanu Gaur will serve as principal financial and accounting officer until a replacement is found.","Geberth remains as consultant during transition; CFGI engaged for advisory support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197945,"accession_number":"0000950170-24-125959","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q3 revenue $5.4M, down 70% YoY; FY2024 guidance cut to $30-35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.4M vs $18.2M prior year, includes $1.2M France recall charge; gross margin fell to 58% from 77%.","Full-year 2024 revenue guidance lowered to $30-35M; expects flat procedure volume growth YoY.","Restructuring reduces workforce & opex ~50%; $3.5M charges in Q4, targeting profitability by end of 2025.","AI VCS revenue up 82% YoY; AUDACITY top-line readout expected by year-end after last patient exited.","Three of four PMA modules filed for Allurion Balloon; France remediation plan completed in September."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":26519000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197944,"accession_number":"0000950170-24-120851","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Allurion converts $7.5M equity investment into revenue interest financing with RTW","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Revenue Interest Financing Agreement (New RIFA) on Oct 30, 2024, converting $7.5M of prior equity purchase into financing.","Financing parties: RTW Master Fund, RTW Innovation Master Fund, RTW Biotech Opportunities Operating Ltd.","New RIFA terms substantially identical to Original RIFA dated Feb 9, 2023; conversion exercised under Side Letter.","Conversion triggered by Oct 22, 2024 election by RTW entities to exercise Investment Conversion in full."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197943,"accession_number":"0000950170-24-117793","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Allurion sets 2024 Annual Meeting for Dec 11; record date Nov 6, proposal deadline Nov 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting of Stockholders set for Wednesday, December 11, 2024.","Record date for voting eligibility is November 6, 2024.","Stockholder proposals under Rule 14a-8 due by November 7, 2024.","Director nominations and universal proxy notices also due by November 7, 2024.","This is Allurion's first annual meeting as a public company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214113,"accession_number":"0000950170-24-104047","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Allurion receives NYSE notice for market cap non-compliance; stock to trade with \".BC\"","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified Allurion avg market cap <$50M over 30 days ended Aug 29, 2024 and equity <$50M.","Company has 45 days to submit a cure plan; if accepted, an 18-month cure period applies.","Common stock continues trading with \".BC\" designation; no immediate delisting.","Allurion also previously received notice on Aug 12, 2024 for non-compliance with minimum closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214112,"accession_number":"0000950170-24-103546","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allurion appoints Eli Lilly veteran Keith Johns to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Johns appointed as Class III director effective Sept 2, 2024; board expands from 7 to 8 members.","Johns spent 25 years at Eli Lilly, most recently leading Global Marketing and Alliance Management for Diabetes and Obesity.","His expertise includes GLP-1 drug launches and obesity market strategy.","Compensation will follow standard non-employee director policy as described in prior SEC filings.","Johns also serves as COO of Adipo Therapeutics, focusing on brown adipose tissue obesity treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214111,"accession_number":"0000950170-24-097653","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Allurion receives NYSE deficiency notice for average stock price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["30-day average closing price below $1.00 as of Aug 8, 2024 triggered NYSE non-compliance notice.","Company has six-month cure period; must close at or above $1.00 on last day of a calendar month with 30-day average above $1.00.","Considering a reverse stock split, subject to stockholder approval, to regain compliance.","No immediate delisting; common stock will trade under symbol ALUR with .BC designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214110,"accession_number":"0000950170-24-095765","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q2 revenue $11.8M, sequential +25%; French regulator suspends Balloon sales; FY guidance lowered to $40-45M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $11.8M, up 25% sequentially from Q1 but down from $13M in Q2 2023.","Operating loss improved to $9.3M from $13.3M in Q2 2023; record procedure volume >10,000 balloon placements for second straight quarter.","ANSM (French regulator) suspended Allurion Balloon sales; company withdrawing from France pending remediation plan on advertising and patient follow-up.","Full-year 2024 revenue guidance reduced to $40-45M from prior; procedure volume growth expected 10-15%.","Cash $19.3M at June 30; completed public offering in July 2024 for ~$22M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":21152000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214109,"accession_number":"0000950170-24-093016","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allurion Balloon sales suspended in France; device withdrawn pending remediation plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["French regulator ANSM suspended sales; Allurion withdrawing device from French market.","Company cites 20 peer-reviewed articles and 150,000+ patients treated to support safety profile.","Complication rates in line with published literature and lower than other weight loss products.","Allurion cooperating with ANSM on remediation plan for advertising, follow-up, and training.","Company disagrees with decision but seeks path to resume commercialization in France."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214108,"accession_number":"0001193125-24-175633","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allurion underwriters partially exercise over-allotment option, add ~$2.3M in gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters partially exercised over-allotment to purchase 1,927,265 additional shares at $1.20/share and accompanying warrant.","Additional gross proceeds of approximately $2.3 million, before underwriting discounts and offering expenses.","Follows previously reported public offering of 14,406,508 shares and 16,567,484 warrants on July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214107,"accession_number":"0001193125-24-173365","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","5.03","3.02","8.01","9.01"],"status":"ready","headline":"Allurion prices $20M public offering and $2.7M private placement with RTW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 14.4M shares + warrants at $1.20/share for $17.3M gross; underwriters have 30-day option for 15% more.","Concurrent private placement: $2.7M to RTW for Series A convertible preferred stock and warrants, subject to stockholder approval.","Total gross proceeds ~$20M before expenses; net proceeds to fund clinical trials, sales, R&D, and working capital.","Closed July 1, 2024; RTW is a significant stockholder and also bought in the public offering (limited to 1% of outstanding).","Series A Preferred Stock non-voting, auto-converts to common upon stockholder approval; mandatory redemption by Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233334,"accession_number":"0001193125-24-168243","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Allurion posts investor presentation on website; content not fully disclosed in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made investor presentation available on its website on June 25, 2024.","Presentation is marked confidential and contains non-public material.","No specific financial metrics, guidance, or strategic updates can be extracted from the provided excerpt.","Filing is under Regulation FD; no material changes or events reported beyond presentation availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233333,"accession_number":"0000950170-24-059102","cik":1964979,"company_name":"ALLURION TECHNOLOGIES, INC.","ticker":"ALUR","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allurion Q1 revenue $9.4M, down 33% YoY but up 14% sequentially; guides FY revenue $60-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.4M, down from $14.1M YoY due to macroeconomic headwinds; procedural volume up 12% YoY and 22% sequentially.","Cash burn $8.4M, down 62% vs Q4 2023; expects ~$30M for full year.","FY 2024 guidance: revenue $60-65M, 13-23% YoY growth; gross margins 77-79%; procedural volume growth 20%.","Closed $48M convertible secured note with RTW Investments in April to simplify capital structure.","Gross profit margin 73% vs 79% YoY on lower production volumes; operating loss $11.4M vs $13.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":9386000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12005003.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}